stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) Operating cash flow
Beam Therapeutics Inc.'s operating cash flow for fiscal 2025 was −$345.1M, compared with −$347.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$388.6M. Over the past ten years it has ranged from −$347.2M (fiscal 2024) to $22.5M (fiscal 2022); the current reading is higher than 22% of that period. Beam Therapeutics Inc. ranks 586th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$345.1M | — |
| FY2024 | −$347.2M | — |
| FY2023 | −$149.2M | — |
| FY2022 | $22.5M | — |
| FY2021 | −$66.3M | — |
| FY2020 | −$95.7M | — |
| FY2019 | −$72.0M | — |
| FY2018 | −$20.3M | — |
| FY2017 | −$2.7M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$110.7M | — |
| Jun 2026 | −$66.1M | — |
| Mar 2026 | −$128.5M | — |
| Dec 2025 | −$83.3M | — |
| 28 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | $51.9M |
| MBX MBX Biosciences, Inc. compare | −$82.7M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$150.5M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$159.2M |
| XNCR Xencor, Inc. compare | −$205.8M |
| VRDN Viridian Therapeutics, Inc. compare | −$341.5M |
| IDYA IDEAYA Biosciences, Inc. compare | −$347.4M |
| BEAM Beam Therapeutics Inc. | −$388.6M |
| RCUS Arcus Biosciences, Inc. compare | −$465.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on BEAM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement